Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE) two randomised, double-masked, phase 3 trials /

Hasonló tételek

• Faricimab Treat-and-Extend for Diabetic Macular Edema Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials /
  Szerző: Wong Tien Y., et al.
  Megjelent: (2024)
• Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON) 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial /
  Szerző: David M Brown, et al.
  Megjelent: (2024)
• Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE) two randomised, double-masked, phase 3, non-inferiority trials /
  Szerző: Heier Jeffrey S., et al.
  Megjelent: (2022)
• Úti emlékek Borbíró Márta fotóalbumából. Képeslapon a Yosemite Nemzeti Park Yosemite-vízesése
• Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema 1‑year results from the Japan subgroup of the phase 3 YOSEMITE trial /
  Szerző: Shimura Masahiko, et al.
  Megjelent: (2023)